乳酸媒介による miRNA 調節 がん治療に対する耐性
Yiyi Shou1,2, Ruiqi Liu3, Hao Xiong1
1Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Journal of translational medicine
|August 20, 2025
まとめ
ラクチレーションは乳酸変異であり,代謝,エピジェネティクス,免疫反応を変化させることで,マイクロRNAと相互作用します. このクロストークをターゲットにすることで 新しい治療戦略と 耐性を予測するバイオマーカーが生まれます
科学分野:
- 癌 生物学
- 代謝 再プログラム
- エピジェネティクス
- 免疫調節
- 翻訳後の修正
- マイクロRNAネットワーク
背景:
- ガンにおける治療抵抗は腫瘍代謝,表遺伝学,免疫調節の複雑な相互作用を伴う.
- ラクチレーションは,乳酸由来の翻訳後の改変であり,代謝の変化と遺伝子発現を結びつける.
- マイクロRNA (miRNA) は代謝適応と表遺伝的可塑性を調節するが,乳化との相互作用は十分に研究されていない.
研究 の 目的:
- がん治療に対するレジスタンスにおける乳糖化-miRNAクロストラックの新興分野を包括的に評価する.
- 乳化とmiRNAが相互作用して腫瘍生物学と治療結果に影響を与えるメカニズムを解明する.
- このクロストークを基に潜在的な治療戦略とバイオマーカーを特定する
主な方法:
- 乳化,miRNA,がん耐性に関する既存の文献のレビューと構造的評価.
- ヒストン/タンパク質とmiRNAネットワークの乳化を含む規制枠組みの分析.
- 乳化に依存するmiRNAの細胞外小胞によるシグナル伝達とその腫瘍微環境への影響の検討.
主要な成果:
- 乳酸化は腫瘍性miRNAを活性化させ,これにより,糖分流と乳酸化酵素の活性が強化され,フィードバックループが形成されます.
- 乳酸の蓄積は,ストレス下にある特定のmiRNAを抑制し,DNA修復と生存のための経路を安定させます.
- 乳化媒介のmiRNA信号はT細胞の枯渇とM2マクロファージの偏化に寄与し,免疫抑制を促進する.
結論:
- ラクティレーションとmiRNAのクロストラックは,がん治療に対する抵抗性における中心的な調節軸である.
- コターゲティング戦略 (例えば,LDHAと腫瘍性miRNA) と液体生検 (H3K18la,miRNAシグネチャー) は治療の可能性を示している.
- メタボリック,エピジェネティック,免疫学的視点の統合は,新しいメカニズム主導のがん介入の開発に不可欠です.
関連する概念動画
MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Epigenetic Regulation
31.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.4K


